Haemonetics (HAE) Other Accumulated Expenses (2010 - 2026)

Haemonetics' Other Accumulated Expenses history runs 17 years deep, the most recent figure standing at $158.3 million for Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 6.89% year-over-year to $158.3 million in Q1 2026; TTM through Mar 2026 was $158.3 million, a 6.89% increase from a year earlier, with the FY2026 full-year figure at $158.3 million, up 6.89% from the prior year.
• Other Accumulated Expenses grew to $158.3 million in Q1 2026 per HAE's latest filing, from $134.3 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $158.3 million in Q1 2026 and bottomed at $85.3 million in Q3 2022.
• The 5-year median for Other Accumulated Expenses is $133.2 million (2023), against an average of $127.3 million.
• Across the five-year window, Other Accumulated Expenses slumped 33.26% in 2022 and jumped 31.6% in 2023, its largest moves.
• Year by year, Other Accumulated Expenses stood at $101.0 million in 2022, then soared by 31.12% to $132.4 million in 2023, then climbed by 5.15% to $139.2 million in 2024, then slipped by 3.52% to $134.3 million in 2025, then rose by 17.87% to $158.3 million in 2026.
• Per Business Quant, the three latest HAE Other Accumulated Expenses figures stand at $158.3 million (Q1 2026), $134.3 million (Q4 2025), and $134.0 million (Q3 2025).